Posted by Michael Wonder on 25 Jun 2020
Sinovac receives approval from China for its quadrivalent influenza vaccine
24 June 2020 - Sinovac Biotech today announced the China National Medical Products Administration issued a product license for its quadrivalent influenza vaccine.
Sinovac expects its quadrivalent influenza vaccine to be available to the China market for the 2020-2021 influenza season.
Quadrivalent Influenza vaccine contains two A strains and two B strains, recommended by the WHO, and the vaccine protects a target group of 3 years and older against the influenza disease.
